• Newly FDA Approved Alzheimer’s Biomarkers Testing: How to Implement Such Tests in Core Laboratory?

  • Oct 21 2024
  • Duración: 36 m
  • Podcast

Newly FDA Approved Alzheimer’s Biomarkers Testing: How to Implement Such Tests in Core Laboratory?

Escúchala gratis

Ver detalles del espectáculo

  • Resumen

  • The diagnostic paradigm for Alzheimer's disease (AD) has rapidly shifted in the last five years as fluid-based biomarker testing has emerged as a reliable, accurate, and accessible means to detect amyloid pathology when evaluating a patient for cognitive decline. This podcast is designed to help pathologists and laboratory professionals gain an understanding of plasma testing for markers such as Abeta40/42, P-tau181, and P-tau217 which are rapidly appearing in the commercial space and how healthcare providers have begun incorporating these tests into routine neurology practice. This podcast will help participants to understand the advantages and limitations of these assays as well as their potential application when a physician is evaluating a patient for AD.

    Más Menos
Más Menos
adbl_web_global_use_to_activate_webcro805_stickypopup

Lo que los oyentes dicen sobre Newly FDA Approved Alzheimer’s Biomarkers Testing: How to Implement Such Tests in Core Laboratory?

Calificaciones medias de los clientes

Reseñas - Selecciona las pestañas a continuación para cambiar el origen de las reseñas.

Reseñas de Audible.com

Opiniones de Amazon
No hay comentarios disponibles